NCT01334203View on ClinicalTrials.gov

A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

PHASE4WithdrawnINTERVENTIONAL

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

December 31, 2012

Conditions

Angina PectorisCoronary Artery DiseaseType 2 Diabetes Mellitus

Interventions

DRUG

Ranolazine

"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."